NCT04723914UnknownPhase 1
Clinical Trial of CD19/CD20 Dual Target CAR-T Cells in the Treatment of Relapsed/Refractory B-cell Lymphoma
YuLi1 site in 1 country20 target enrollmentStarted: October 20, 2020Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Sponsor
- Enrollment
- 20
- Locations
- 1
- Primary Endpoint
- Complete remission rate
Study Overview
Brief Summary
Prospectively evaluate the safety and effectiveness of CD19/CD20 dual-target CAR-T cells in the treatment of relapsed/refractory B-cell lymphoma .
Detailed Description
Prospectively evaluate the safety and effectiveness of CD19/CD20 dual-target CAR-T cells in the treatment of relapsed/refractory B-cell lymphoma . Strictly follow the inclusion criteria to screen eligible subjects for inclusion in clinical trials. The selected patients received CD19/CD20 dual-target CAR-T cell therapy. After the treatment is over, follow-up regularly to determine the survival status and follow-up treatment.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 14 Years to 75 Years (Child, Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Subjects must meet the following criteria to participate in this study:
- •14-75 years old, no gender limit;
- •Diagnosed as relapsed/refractory B-cell lymphoma according to the 2020 World Health Organization (WHO) diagnostic criteria;
- •ECOG behavior status score is 0-2 points;
- •Expected survival time ≥ 3 months;
- •No contraindications to peripheral apheresis;
- •Flow cytometry/immunohistochemistry confirms that tumor cells express CD20;
- •Those who are tolerant to CD19 CAR-T cell therapy or those with low CD19 expression;
- •No serious heart, lung, liver or kidney disease;
- •Ability to understand and willing to sign the informed consent form for this trial.
Exclusion Criteria
- •Patients with any of the following cannot be included in this study:
- •Tumor cells do not express CD20;
- •There is active infection;
- •Abnormal liver function (total bilirubin>1.5×ULN, glutamic-pyruvic transaminase>2.5×ULN), abnormal renal function (serum creatinine>1.5×ULN);
- •People with unstable angina or New York Heart Association class 3/4 congestive heart failure, multiple organ dysfunction;
- •HIV/AIDS patients;
- •Those who need long-term anticoagulation (warfarin or heparin), antiplatelet (aspirin, dose>300mg/d; clopidogrel, dose>75mg/d) treatment;
- •Those who received radiotherapy within 4 weeks before the start of the study (blood sampling);
- •Known or suspected drug abuse or alcohol dependence;
- •People with mental illness or other conditions cannot obtain informed consent, and cannot cooperate with the requirements for completing the experimental treatment and inspection procedures;
- •Those who have participated in other clinical trials within 30 days;
- •Pregnant or lactating women, male subjects (or their partners) or female subjects have a pregnancy plan during the study period to 6 months after the end of the test, and are unwilling to use a medically approved effective contraceptive measure during the test period (Such as intrauterine device or condom);
- •The investigator judged that it is not suitable to participate in this trial.
Outcomes
Primary Outcomes
Complete remission rate
Time Frame: From date of initial treatment to the end of follow up, up to 2 years
All visible lesions disappeared completely and maintained at least 4 weeks.
Secondary Outcomes
- Overall survival rate(From admission to the end of follow up, up to 2 years)
Investigators
YuLi
Professor
Shenzhen University General Hospital
Study Sites (1)
Loading locations...
Similar Trials
Unknown
Phase 1
Dual Target CAR-T Cells in B-cell Acute Lymphoblastic LeukemiaDual-target CAR-T CellsB ALLRelapseRefractory B Acute Lymphoblastic LeukemiaNCT04723901Shenzhen University General Hospital20
Suspended
Early Phase 1
CD19/CD20 Dual-CAR-T in B-cell Non-Hodgkin's Lymphoma Patients.B-cell Non-Hodgkin's LymphomaNCT04697290Beijing Tsinghua Chang Gung Hospital12
Unknown
Early Phase 1
Safety and Efficacy of CD19/CD22 Dual Targeted CAR-T Cell Therapy in R/R B-Cell Acute Lymphoblastic LeukemiaCD19+ and CD 22+ B-ALLNCT05225831Hebei Senlang Biotechnology Inc., Ltd.100
Recruiting
Phase 1
Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage LeukaemiaLymphoblastic LeukemiaLymphoblastic Leukemia, Acute, ChildhoodLymphoblastic Leukemia in ChildrenLymphoblastic Leukemia, Acute AdultCARNCT05429905KK Women's and Children's Hospital48
Active, not recruiting
Phase 2
CAR-T Followed by Bispecific AntibodiesLarge B-cell LymphomaDLBCL - Diffuse Large B Cell LymphomaNCT04889716Abramson Cancer Center at Penn Medicine23